Clinical trials located in

Vigo

Vigo city is located in Spain. Currently, 20 clinical trials are being conducted in this city.

Vigo, nestled in the northwest of Spain, is Galicia’s largest city, boasting a rich maritime heritage. It’s renowned for its bustling port, one of the world’s leading fishing ports, and the gateway to the stunning Cíes Islands, part of the Atlantic Islands of Galicia National Park. The city’s history is vividly captured in its ancient streets, with remnants of its Roman past. Vigo is also celebrated for its vibrant cultural scene, including the Reconquista festival, which commemorates its resistance against French troops in 1809.

  • CT-EU-00041556

    New therapy trial for relapsed large B-cell lymphoma

    This study is testing the use of two different treatments for diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. Group One receives a mix of drugs, including polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide (collectively called Pola-R-ICE). Group Two receives a similar mix without polatuzumab vedotin, known as R-ICE. Patients will be randomly sorted into the two groups. The test treatment spans three months and includes three chemotherapy treatments. After that, doctors will follow up with patients for at least 21 months. The goal is to compare how well the two treatments work to control DLBCL. Different factors, like progress of the disease, the response to treatment, and overall health will be observed to determine how efficient these treatments are.

    • Mabthera
    • Ifosfamide
    • Polatuzumab vedotin
    • Etoposide
    • Carboplatin
  • Study relating to new treatment for ovarian cancer

    This is a study for patients who have ovarian, fallopian tube, or primary peritoneal cancer that has resisted platinum-based treatments. The main goal is to see how well two drugs, Nemvaleukin Alfa and Pembrolizumab, work together compared to other chemotherapy treatments that the doctor chooses. Patients will be picked randomly by a computer to receive either the two-drug combo, one of the two drugs alone, or other chemo drugs, such as doxorubicin, paclitaxel, topotecan, or gemcitabine. This study is open, which means everyone will know which treatment is being given.

    • Nemvaleukin
    • Pegylated Liposomal Doxorubicin
    • Pembrolizumab
    • topotecan
    • Gemcitabine
    • Paclitaxel
  • Osimertinib effectiveness study for early-stage lung cancer post-surgery

    This study is examining the effects of osimertinib on patients with a specific type of early-stage lung cancer (EGFRm stage IA2-IA3 non-small cell lung cancer) after complete tumor removal surgery. It’s a Phase III trial comparing osimertinib, a new drug, with a placebo. Participants, who have already had surgery for their lung cancer, will either receive osimertinib or a placebo daily for three years. The goal is to see if osimertinib can prevent cancer from coming back and improve patients’ survival rates.

    • Osimertinib
  • CT-EU-00041922

    Testing new medication for adult muscle inflammation treatment

    This study aims to test a medicine called Efgartigimod (EFG PH20 SC) for adults who are suffering from a disease called Idiopathic Inflammatory Myopathy (IIM), where muscles become inflamed for unknown reasons. This condition often falls into groups like dermatomyositis, immune-mediated necrotizing myopathy, or specific types of polymyositis. The trial wants to compare how good the medicine is against a placebo. The researchers will look at how much people’s symptoms improve and whether there are any side effects. The test is going to be carried out in many locations and will involve people over 18 years old.

    • Efgartigimod/ EFG PH20 SC
  • Research on plitidepsin effectiveness in treating COVID-19

    This research study aims to investigate the benefits and safety of a drug called plitidepsin for COVID-19 patients who have a weakened immune system and require hospital care. The study will administer the drug to some patients, while others will receive standard care, allowing researchers to assess whether plitidepsin can reduce death rates in this specific population. Throughout the study, close monitoring will be conducted to observe any changes, including side effects, serious incidents, or the necessity to discontinue the treatment.

    • Plitidepsin
  • Study on a new combination therapy for active ulcerative colitis

    This study aims to assess the effectiveness and safety of new combination therapy with JNJ-78934804 (Guselkumab/Golimumab) in comparison to guselkumab and golimumab administred alone for individuals with moderately to severely active ulcerative colitis. Participants who have shown inadequate response, loss of response, or intolerance to approved advanced therapies will be included. The trial includes various treatment groups: placebo, Guselkumab, Golimumab, and different doses of JNJ-78934804. All participants meeting inadequate response criteria will be escalated to an active treatment. The study will last for 48 weeks and the progress will be tracked over this period. The primary focus is to evaluate the efficacy and safety of the different doses of new therapy in managing ulcerative colitis over the course of the study.

    • JNJ-78934804/guselkumab + golimumab
    • Golimumab
    • Guselkumab
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    • Milvexian
  • Testing Milvexian’s effectiveness in preventing repeat strokes

    This research trial, called LIBREXIA-STROKE, will test a medication called Milvexian on those who have recently had a stroke or a high-risk ‘mini-stroke’. In its 3rd testing phase, the study will involve a system where the patients won’t know whether they are receiving the actual drug or a substitute with no effect, referred to as a ‘placebo’, to maintain fairness. Milvexian is a medication that can potentially reduce the risk of having another stroke, and this trial aims to observe how effective it is in doing so. The trial will look at when the first stroke happens after starting the trial, if other major heart or limb diseases occur, or if strokes occur in the first 90 days.

    • Milvexian
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    • Olpasiran
  • Testing venglustat for heart condition in Fabry disease patients

    This study is about a medicine called venglustat, and how it affects the size of the left side of the heart for people with a disease called Fabry. The trial will have men and women with Fabry disease, who will either get venglustat or the current commonly used treatments. The aim is to investigate whether venglustat can induce changes in the size of the left side of the hearts. The trial will last for 18 months, with check-ups every 3 to 6 months. After the first 18 months, patients can choose to get venglustat for 34 more months. So, the whole study could last up to 4.4 years for some people.

    • Agalsidase beta/GZ419828
    • Venglusat/GZ402671
    • Agalsidase alfa
    • Migalastat
  • Evaluating treatment strategies for small-cell lung cancer: A clinical trial with lurbinectedin, irinotecan, and topotecan

    This is a large test the researchers are running to help people with a certain type of lung cancer (called Small-cell Lung Cancer) that’s come back after they’ve had one type of treatment that contains platinum. The researchers are using three different ways of giving medicine to see which is best. The first way is to give only lurbinectedin. The second way is to give lurbinectedin and irinotecan together. The third way is to let the doctor decide to use topotecan or irinotecan alone. People’s selection to these groups will be by chance.

    • Irinotecan
    • topotecan
    • Lurbinectedin
  • Inhaler treatment study for Mycobacterium Avium complex lung infection

    This study is for adults with lung infections caused by Mycobacterium avium complex. It tests a new inhalation treatment, ALIS (amikacin liposome inhalation suspension), in combination with standard drugs, azithromycin and ethambutol. The aim is to see if ALIS improves respiratory symptoms better than the standard treatment alone. Participants will receive either ALIS or a placebo, along with the standard drugs. The study focuses on safety, symptom improvement, and overall health impact. This research is important for finding more effective treatments for these challenging lung infections.

    • ALIS (amikacin liposome inhalation suspension)
    • Azithromycin
    • Ethambutol
  • Testing eptinezumab for children’s migraine relief

    This study aims to test a new treatment called Eptinezumab in children aged 6 to 17 years diagnosed with Episodic Migraine, which is a type of headache that happens less than 15 days a month. The treatment involves a single intravenous infusion of Eptinezumab that may be either 100 mg or 300 mg. The study is randomized, double-blind, placebo-controlled, and estimated to enroll 315 participants. The primary goal is to determine the efficacy and safety of Eptinezumab in pediatric patients, and the study will look at the change in the number of monthly migraine days after receiving the treatment. Secondary outcome measures include percentage reduction in migraine days, the presence of migraine after dosing, the change in the number of monthly headache days, and plasma Eptinezumab concentrations.

    • Eptinezumab
  • Long-term safety & efficacy study for Ianalumab in Sjogrens syndrome

    This study is testing a drug called ianalumab to see if it can help people with Sjogren’s syndrome. Participants will receive the drug once a month or once every three months. The study will last approximately five years. It involves taking the drug for three years and then being followed by researchers for another two years. Doctors are interested in whether the drug will work for a long time and whether it will be safe. What is important is that the study participants will be patients who have already completed the previous trial. If a patient received placebo treatment in the previous study, they will now receive the real drug once a month or once every three months. The most significant thing is to understand how this drug helps Sjogren’s syndrome eventually.

    • VAY736 (Ianalumab)
  • Examining the effectiveness of a new medicine for recent heart attack patients

    This trial is focused on a medicine called BI 765845, and it aims to determine its effectiveness for individuals who have experienced a heart attack. The objective is to assess the effectiveness of different quantities of the medicine when administered to these patients. Participation is limited to adults who have recently suffered a heart attack. During the study, some participants will receive the medicine, while others will be administered a placebo. The placebo lacks any medicinal properties. The likelihood of receiving the real medicine is four times greater than receiving the placebo. Over the next three months, participants will be requested to make multiple visits to the study site for heart health assessments. Any side effects will be documented and regularly monitored. The goal is to compare the results between the medicine and the placebo to determine which one is more effective.

    • BI 765845- new potential medication for ST segment-elevation myocardial infarction
  • Belimumab study for systemic sclerosis-lung disease

    This study evaluates belimumab’s efficacy and safety compared to a placebo in treating systemic sclerosis-associated interstitial lung disease (SSc-ILD). Approximately 300 participants will receive belimumab or a placebo alongside standard therapy. The main focus is on the drug’s impact on lung function, skin thickening, and symptoms affecting quality of life, like fatigue. The study aims to provide insights into better managing SSc-ILD, improving patient outcomes.

    • Belimumab
  • Testing the safety and effectiveness of a new drug in adults with atopic dermatitis

    This trial involves the exploration of a new medication, GSK1070806, for adults afflicted with moderate to severe atopic dermatitis, a skin condition characterized by redness and itching. Over a 16-week period, participants are administered either the new medication or a placebo, a substance devoid of therapeutic properties. This double-blind study ensures that neither the participant nor the doctor is aware of the treatment allocation. Parameters assessed include the medication’s efficacy, safety, drug metabolism within the body, and its impact on the disease. An essential metric is the EASI score, reflecting the severity of the skin condition. Additional assessments encompass the evaluation of itchiness levels, pain intensity, and the disease’s effect on sleep and fatigue. Physicians also document any adverse events, which pertain to unexpected medical incidents related to the drug, and ascertain causality.

    • GSK1070806- new potential medication for chronic inflammatory conditions
  • Evaluating safety and effects of anifrolumab in systemic sclerosis treatment

    The DAISY trial, a phase III study, is focused on evaluating the use of anifrolumab in the treatment of systemic sclerosis in adults. Its purpose is to measure the effectiveness and safety of the drug and observe its effect on symptoms and progression of the disease. Participants undergo comprehensive screening, treatment and follow-up. The study specifically focuses on response to treatment, changes in lung function and potential side effects, providing important information on the treatment of systemic sclerosis.

    • Anifrolumab

See more clinical trials in other cities in Spain:

.